331 related articles for article (PubMed ID: 29596070)
1. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
2. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
Pich A; Riera L; Sismondi F; Godio L; Davico Bonino L; Marmont F; Francia di Celle P
J Clin Pathol; 2009 Sep; 62(9):798-801. PubMed ID: 19734476
[TBL] [Abstract][Full Text] [Related]
4. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
5. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
[TBL] [Abstract][Full Text] [Related]
6. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
[TBL] [Abstract][Full Text] [Related]
7. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
[TBL] [Abstract][Full Text] [Related]
8. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
10. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
13. Comparison of JAK2
Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
[TBL] [Abstract][Full Text] [Related]
14. JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan.
Sultan S; Irfan SM
Asian Pac J Cancer Prev; 2015; 16(17):7889-92. PubMed ID: 26625816
[TBL] [Abstract][Full Text] [Related]
15. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.
Kekre N; Ho VT
Am J Hematol; 2016 Jan; 91(1):123-30. PubMed ID: 26453238
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease.
Wang SA; Galili N; Cerny J; Sechman E; Chen SS; Loew J; Liu Q; Fadare O; Hasserjian R; Jones D; Qawi H; Woda B; Raza A
Am J Clin Pathol; 2006 Nov; 126(5):789-97. PubMed ID: 17050076
[TBL] [Abstract][Full Text] [Related]
18. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
Khan M; Muzzafar T; Kantarjian H; Badar I; Short N; Wang X; Chamoun K; Jain P; DiNardo C; Pemmaraju N; Bose P; Borthakur G; Cortes J; Verstovsek S; Garcia-Manero G; Estrov Z
Ann Hematol; 2018 Jul; 97(7):1183-1191. PubMed ID: 29557496
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.
Petrova-Drus K; Chiu A; Margolskee E; Barouk-Fox S; Geyer J; Dogan A; Orazi A
Oncotarget; 2017 Nov; 8(61):103274-103282. PubMed ID: 29262560
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
